Related by context. All words. (Click for frequent words.) 77 Protectan CBLB# 71 NEUMUNE 71 Protexia R 68 AEOL # 68 Homspera 67 Anthim 67 Restanza 67 Valortim 65 SparVax TM 64 eniluracil 64 RDEA# 64 ganetespib 63 Prochymal 63 Cleveland BioLabs 63 Valortim R 62 PXD# 62 Valortim ® 62 CGEN # 62 AP# [003] 62 IMVAMUNE R 62 Azedra 62 MAXY G# 61 bafetinib 61 OncoVEX GM CSF 61 Acute Radiation Syndrome ARS 61 bavituximab 61 Alpharadin 61 preclinical efficacy 61 rBChE 61 Protectan 61 MGCD# [001] 61 CR# vcMMAE 61 Protexia ® 61 AVP #D# 61 PEG SN# 60 ATL# [001] 60 Radilex 60 Bezielle 60 HCV protease inhibitor 60 Traficet EN 60 NP2 Enkephalin 60 Tamibarotene 60 Menerba 60 ANAVEX #-# [001] 60 Amigal 60 Cethrin 60 RiVax TM 60 Chemophase 60 PROSTVAC TM 60 masitinib 60 HspE7 60 XmAb# 60 HGS ETR1 60 Sym# 60 Tarvacin TM 60 raxibacumab 60 Archexin 59 Neumune 59 PEG Interferon lambda 59 Perifosine 59 PCK# 59 PMX # 59 tanespimycin 59 voreloxin 59 ISTODAX 59 TACI Ig 59 AEG# 59 Carfilzomib 59 CEQ# 59 BAY #-# 59 RiVax 59 ASONEP 59 SparVax ™ 59 huC# DM4 59 Tarvacin 59 RiVax ™ 59 MEK inhibitor 59 preclinical toxicology 59 Ebola SNALP 59 #ME# 59 sapacitabine 59 OXi# 59 IND submission 59 Cotara 59 rPA anthrax vaccine 59 HQK 59 cilengitide 58 TKM Ebola 58 CoFactor 58 GFT# 58 Cethromycin 58 OncoVEX 58 GRN#L 58 anticoagulant reversing agent 58 EOquin TM 58 anticancer agent 58 iSONEP 58 BiTE antibody 58 Civacir 58 PF # [001] 58 oral prodrug 58 DXL# 58 PRX# 58 ALN VSP 58 Neuradiab 58 vemurafenib 58 carfilzomib 58 methylnaltrexone 58 rPA 58 torezolid phosphate 58 Fodosine 58 GLP toxicology studies 58 obatoclax 58 CCX# 58 ALN TTR# 58 ANAVEX #-# [003] 58 AZX# 58 IMA# 58 pharmacokinetic PK study 58 tesetaxel 58 Nanobody ® 58 Reolysin 58 Triolex 58 systemically administered 58 IDX# 58 ISIS # 58 Phase Ib study 58 ELACYT 58 pomalidomide 57 R#/MEM # 57 Onalta 57 Phase Ib 57 perifosine 57 ALN TTR 57 MGd 57 otelixizumab 57 vilazodone 57 SCH # 57 INCB# [001] 57 JAK inhibitor 57 Bicifadine 57 forodesine 57 TRIOLEX 57 blinatumomab 57 proteasome inhibitor 57 thymalfasin 57 IMGN# 57 H#N# VLP vaccine 57 Elesclomol 57 Revimmune 57 rilonacept 57 IRX 2 57 Vidaza 57 Nanobody 57 HuMax CD4 57 favorable pharmacokinetic profile 57 Phase 1b 57 PROCHYMAL 57 AEZS 57 CIMZIA TM 57 Aplidin 57 CTCE 57 Multikine 57 tamibarotene 57 EndoTAG TM -1 57 CYT# 57 Phase IIB 57 belinostat 57 ADVEXIN 57 DAVANAT R 57 registrational 57 pharmacodynamic PD 57 RAV# 57 Hollis Eden 57 NEBIDO 57 PSMA ADC 57 BioNumerik 57 valopicitabine 57 AZD# 57 phase IIb clinical 57 indibulin 57 Mipomersen 57 mapatumumab 57 Urocidin 57 targeted radiotherapeutic 57 INT# [002] 56 Advexin 56 INCB# [002] 56 Panzem 56 trabectedin 56 VEGF Trap 56 Protexia 56 pharmacokinetic studies 56 Lenocta 56 Phase #b/#a 56 imetelstat 56 Onconase 56 HuMax EGFr 56 Dr. Fonstein 56 tezampanel NGX# 56 CD# antibody [001] 56 Fx #A 56 Bendavia 56 TNFerade 56 Zalypsis 56 ofatumumab 56 nanoviricides 56 atacicept 56 CCR5 mAb 56 Guanilib 56 Golimumab 56 Exelixis XL# 56 Rexin G 56 oral antiviral 56 Tesetaxel 56 MOR# 56 CA4P 56 YONDELIS 56 hGH CTP 56 Fast Track Status 56 nitazoxanide 56 orBec 56 Capesaris 56 pharmacodynamic 56 Azedra TM 56 Ampligen R 56 CORT # 56 immune modulatory 56 BiovaxID 56 enzastaurin 56 MVA BN R 56 tesmilifene 56 fosbretabulin 56 PLX# 56 MEK inhibitors 56 Symadex 56 CBLI 56 tezampanel 56 preclinically 56 elotuzumab 56 PEGylated interferon 56 Abiraterone acetate 56 synthetic retinoid 56 Aurexis 56 ixabepilone 56 IMVAMUNE ® 56 PLK1 SNALP 56 Curaxin 56 SPC# [001] 56 mertansine 56 TG# [003] 56 MAGE A3 ASCI 56 Alocrest 56 GRN# 56 lintuzumab 56 Trofex 56 Phase 2a trial 56 HGS ETR2 56 Excellarate 56 GeoVax vaccine 56 depsipeptide 56 CD# monoclonal antibody 56 leading oral taxane 56 immunotherapeutic 56 PI3K inhibitor 56 NEUGENE 56 Altastaph 56 Allovectin 7 56 RNAi therapeutic 56 SAR# [004] 56 Imprime PGG 56 REOLYSIN ® 56 ELND# 56 delafloxacin 55 liposomal formulation 55 Vaxfectin 55 Virulizin ® 55 TREANDA 55 ZYBRESTAT 55 Bortezomib 55 Spiegelmer ® 55 panitumumab 55 FDA Orphan Drug 55 MDV# 55 IAP inhibitors 55 anticancer compound 55 dose cohorts 55 LibiGel Phase III 55 amrubicin 55 CRLX# 55 velafermin 55 RIGScan CR 55 CBLC# 55 phase Ib 55 Omacetaxine 55 Atiprimod 55 axitinib 55 Dapagliflozin 55 Proxinium TM 55 HuMax CD# 55 Exherin TM 55 T DM1 55 immunomodulator 55 ALKS 55 GSK# [001] 55 L BLP# 55 registrational trial 55 milatuzumab 55 NexACT 55 trastuzumab DM1 T DM1 55 GLPG# 55 PKC# 55 GLP toxicology 55 radezolid 55 Zolinza 55 FluCide 55 Valortim TM 55 Panzem R NCD 55 MORAb 55 ALN RSV# 55 Microcyn Technology 55 glufosfamide 55 Spheramine 55 OvaRex ® MAb 55 phase IIa clinical 55 HCD# [002] 55 bortezomib Velcade 55 Allovectin 7 ® 55 investigational monoclonal antibody 55 Amrubicin 55 preclinical studies 55 Curaxin CBLC# 55 oritavancin 55 lomitapide 55 Factor VIIa 55 PDE4 inhibitor 55 Phenoptin 55 anthrax monoclonal antibody 55 Prodarsan ® 55 decitabine 55 Relivar 55 IMC A# 55 JAK inhibitors 55 Serdaxin 55 NPC 1C 55 OvaRex R 55 LY# [003] 55 NGX# 55 cannabinor 55 ospemifene 55 AQ4N 55 BNC# 55 RG# [001] 55 PLX cells 55 viral kinetics 55 veltuzumab 55 OHR/AVR# 55 Blinatumomab 55 Phase IIIb clinical 55 ATL# [002] 55 Xanafide 55 Genasense ® 55 BrachySil 55 Voreloxin 55 PEG PAL 55 histone deacetylase inhibitor 55 EOquin 55 therapeutic monoclonal antibodies 55 deforolimus 55 TRO# 55 omacetaxine 55 anti CD3 antibody 55 KNS # 55 MAP# 55 EVIZON 55 PS# [001] 55 Sphingomab 55 Arikace 55 ThGRF 55 Hedgehog antagonist 55 BioVant 55 RAPAFLO 55 targeting CD# 55 IAP inhibitor 55 rindopepimut 55 Debio 55 ONCONASE 55 small molecule defensin 54 Zysolin TM 54 GALNS 54 Ceflatonin 54 Locteron 54 nicotinic alpha 7 54 AeroLEF TM 54 teduglutide 54 SPIRIVA HandiHaler 54 alvimopan 54 ATL/TV# 54 mAbs 54 Tarceva TM 54 Apoptone 54 LUVENIQ 54 AMD# [003] 54 vascular disrupting agents 54 Vilazodone 54 pexiganan 54 FOLOTYN 54 BAL# [002] 54 Radezolid 54 Fentanyl TAIFUN R 54 Cleveland Biolabs 54 UPLYSO 54 preclinical 54 antisense drug 54 Crofelemer 54 recombinant subunit vaccine 54 Darinaparsin 54 Aclidinium 54 vidofludimus 54 HCV protease inhibitors 54 vivo efficacy 54 Hycamtin 54 elacytarabine 54 Phase IIa clinical 54 MGN# 54 PSN# [002] 54 TELINTRA 54 RNAi Therapeutic 54 AzaSite Plus 54 OMP #M# 54 dose cohort 54 Cloretazine ® 54 Lovaxin C 54 nalbuphine ER 54 Tyrima 54 velafermin belinostat 54 Cladribine Tablets 54 Tanespimycin 54 Tβ4 54 Phase 2a 54 PRT# 54 PRTX 54 PEGylated 54 Plenaxis TM 54 multiple ascending dose 54 Phase #b/#a clinical 54 sulodexide 54 immunomodulatory properties 54 GED aPC 54 StemEx R 54 Phase 2b trial 54 celgosivir 54 JAK3 54 metaglidasen 54 MEK inhibitor RDEA# 54 TELCYTA 54 diabetic neuropathic pain 54 albinterferon alfa 2b 54 MAXY alpha 54 defensin mimetic antibiotic 54 Amplimexon 54 Zelrix 54 Synavive 54 GLYX 54 LymphoStat B 54 Azixa 54 Posiphen 54 Marqibo 54 KRN# 54 immunomodulatory 54 ZFP Therapeutic 54 Dacogen injection 54 Opexa 54 cancer immunotherapies 54 therapeutic monoclonal antibody 54 CK # 54 tolerability profiles 54 Cetrorelix 54 XL# [003] 54 Allovectin 7 R 54 talactoferrin 54 orally bioavailable 54 intranasal delivery 54 OMAPRO 54 Phase IIa trial 54 bioscavenger 54 Phase IIb clinical trials 54 Phase 2b clinical 54 humanized anti 54 biodefense countermeasure 54 ROTARIX 54 aflibercept 54 ThermoDox ® 54 alvespimycin 54 docetaxel Taxotere R 54 generation antisense 54 Litx 54 ENMD # 54 immune stimulatory 54 pradefovir 54 Plicera 54 BioThrax 54 HGS# 54 uric acid lowering 54 dalbavancin 54 TKM ApoB 54 Viprovex TM 54 glucokinase activator 54 brentuximab vedotin SGN 54 CUDC 54 MultiStem 54 Phase 1a 54 dose escalation Phase 54 pharmacokinetic characteristics 54 ThermoDox 54 dosing cohort 54 alagebrium 54 #I TM# 54 selective modulator 54 Ophena TM 54 Urocidin TM 54 Dasatinib 54 posaconazole 54 EGEN 54 rFVIIIFc 54 therapeutic antibody 54 BLA filing 54 eltrombopag 54 RECOTHROM 54 NEUGENE antisense 54 Pralatrexate 54 Universal Flu Vaccine 54 anti leukemic 54 Cerashield 54 Apaziquone 54 Laquinimod 53 Orphan Drug designations 53 thiazolides 53 Androxal TM 53 ridaforolimus 53 FOLFOX chemotherapy 53 Stimuvax 53 laquinimod 53 hematological malignancies 53 OMP #R# 53 tecarfarin 53 Genasense 53 NKTR 53 NN# [001] 53 Nimotuzumab 53 Virulizin R 53 confirmatory Phase 3 53 vorinostat 53 immunotherapeutic vaccine 53 oncolytic viruses 53 molecularly targeted 53 drug GAP #B# 53 IIa trial 53 TG# [001] 53 ON #.Na 53 ZADAXIN 53 IMC #B 53 Zerenex 53 Icatibant 53 Bioral Amphotericin B 53 NTDDS 53 TYZEKA 53 PEGPH# 53 Restanza TM 53 IND enabling 53 ANA# 53 PrevOnco ™ 53 TOCOSOL Paclitaxel 53 dexpramipexole 53 BCX# 53 VAPRISOL 53 pharmacokinetic 53 Xcytrin 53 omega interferon 53 maribavir 53 siRNA therapeutic 53 Onco TCS 53 prodrug 53 Erbitux cetuximab 53 Phase IIa trials 53 samalizumab 53 Zybrestat 53 APOPTONE 53 AEGR 53 rFIXFc 53 DPX Survivac 53 StemEx 53 vismodegib 53 Indaflex TM 53 Myocet 53 alkylating agent 53 Onalta ™ 53 brivaracetam 53 RSD# 53 ALN PCS 53 Ostarine 53 histone deacetylase HDAC inhibitor 53 cytostatic 53 radiation countermeasure 53 Ampligen ® 53 oral formulation 53 Viramidine 53 dose escalation 53 Rasagiline 53 subcutaneously administered 53 PHX# 53 radiolabeled TM# 53 liprotamase 53 adenovector 53 radiolabeled monoclonal antibody 53 phase IIa 53 zalutumumab 53 Aflibercept 53 Xcytrin R 53 phase IIb trial 53 Japanese Encephalitis vaccine 53 RECOTHROM R 53 pharmacokinetic profile 53 BARDA 53 Diamyd ® 53 pralatrexate 53 Anidulafungin 53 Phase III Pivotal 53 ZK EPO 53 TriRima 53 Hsp# inhibitor 53 Phase 1b trial 53 CG# [003] 53 ApoB SNALP 53 anti CD# antibody 53 PROVENGE sipuleucel T 53 tgAAC# 53 confirmatory Phase III 53 clinical pharmacology studies 53 exon skipping 53 vosaroxin 53 ENMD 53 CRx 53 DermaVir Patch 53 Veronate 53 Trastuzumab 53 Panzem R 53 Voraxaze 53 Folotyn 53 CDDO Im 53 CLORETAZINE TM VNP#M 53 AVN# [001] 53 anticancer agents 53 Viprinex 53 biodistribution 53 GeoVax AIDS vaccine 53 ipilimumab 53 Telavancin 53 Aganocide 53 oncolytic 53 Bavituximab 53 Phase 2a clinical 53 Forodesine HCl 53 selective androgen receptor modulator 53 Chrysalin 53 davunetide 53 GVAX 53 Kahalalide F 53 oral rivaroxaban 53 RSD# oral 53 nanopharmaceutical 53 BLA submission 53 Cardio Vascu Grow 53 INGN 53 budesonide foam 53 romidepsin 53 cancer immunotherapy 53 phase IIb 53 Nexavar ® 53 CCR5 antagonist 53 Onrigin 53 solithromycin 53 Phase Ib II 53 potent anticancer 53 Resten NG 53 Belinostat 53 ORMD 53 Aptivus ® 53 MT#/MEDI-# 53 ALGRX 53 urocortin 2 53 Rhucin ® 52 JAK2 inhibitor 52 viral kinetic 52 orally dosed 52 PREOS R 52 subcutaneous formulation 52 mitogen activated ERK kinase 52 siRNA therapeutics 52 antibody MAb 52 immunotoxins 52 GTC recombinant human 52 EGS# 52 proteasome inhibitors 52 ABRAXANE ® 52 granisetron 52 Telaprevir 52 RhuDex ® 52 SNALP technology 52 Octreotide 52 tranilast 52 DP b# 52 anticancer 52 relapsed multiple myeloma 52 Arimoclomol 52 investigational compound 52 TRV# [001] 52 laninamivir 52 RenaZorb TM 52 orally administered inhibitor 52 oral ridaforolimus 52 RNAi therapeutic targeting 52 ponatinib 52 triphendiol 52 Lipid Sciences 52 Inhalation Solution 52 anti EGFR antibody 52 CRD5 52 Surfaxin LS 52 Naproxcinod 52 incyclinide 52 menadione 52 low dose cytarabine 52 anticancer therapy 52 ACAM# 52 chemotherapeutic drug 52 rPA vaccine 52 Development Authority BARDA 52 demonstrated antitumor activity 52 tolerability profile 52 IL# PE#QQR 52 palifosfamide 52 Anticalins 52 Pathway Inhibitor 52 Interferon alpha 52 RGB # 52 orphan designation 52 Tovaxin 52 immune modulation 52 Elagolix 52 lucinactant 52 afatinib 52 HCV nucleotide polymerase inhibitor 52 antigen sparing 52 nimotuzumab 52 satraplatin 52 COTI 52 APF# 52 investigational pan BCR 52 DAVANAT ® 52 teplizumab 52 PTH analogue 52 pafuramidine 52 novel anticancer 52 biodefence 52 DCCR 52 CIMZIA ™ 52 EndoTAG TM 52 BENLYSTA ® 52 Pimavanserin 52 JVRS 52 inhibitor RG# 52 GRNVAC1 52 Ridaforolimus 52 antineoplastic 52 KSP inhibitor 52 Phase #/#a trial 52 FavId 52 hormone LHRH antagonist 52 Fibrillex TM 52 mAb 52 MGCD# [002] 52 radiotherapeutic 52 ATryn R 52 vascular disrupting agent 52 bevirimat 52 Gemcitabine 52 omecamtiv mecarbil 52 immunotherapeutics 52 eculizumab 52 BEMA Fentanyl 52 SNT MC# 52 Ceflatonin R 52 AeroLEF 52 vascular disrupting 52 pharmacodynamics 52 QLT# 52 Medical Countermeasure 52 immune modulator 52 GAP #B# 52 Ketotransdel 52 nanoviricide 52 Thiovir 52 TransVax ™ 52 custirsen 52 PDX pralatrexate 52 Elusys 52 receptor tyrosine kinase inhibitor 52 crofelemer 52 ARIKACE 52 SUCCEED trial 52 PROMACTA 52 angiogenesis inhibitor 52 synthetic siRNA 52 ARRY 52 TB4 52 FTY# 52 HSP# inhibitor 52 dacetuzumab 52 Clolar ® 52 reslizumab 52 immunogenicity 52 ESBA# 52 Asentar 52 DACH platinum 52 TMC# [002] 52 Ceplene/IL-2 52 SomatoKine 52 CIP TRAMADOL ER 52 Phase III 52 Crizotinib 52 New Drug IND 52 TOLAMBA 52 aclidinium 52 seliciclib 52 DOS# 52 NOX E# 52 ANG# 52 mGluR5 NAM 52 investigational humanized monoclonal antibody 52 superficial bladder cancer 52 Orphan Status 52 edoxaban 52 investigational drug 52 polymerase inhibitors 52 NOXXON 52 Vorinostat 52 motexafin gadolinium Injection 52 aflibercept VEGF Trap 52 Tarmogen 52 Genasense ® oblimersen 52 elagolix 52 integrase inhibitor 52 Melphalan 52 REP# 52 Nanobodies ® 52 Alzhemed TM 52 HCV protease 52 Tß4 52 stated Michelle Berrey 52 humanized monoclonal antibody 52 Telatinib 52 THALOMID 52 Behcet uveitis 52 chimeric monoclonal antibody 52 oncolytic virus 52 BEMA TM Fentanyl 52 cyclosporin 52 ONCONASE R 52 PRX # 52 calcitonin 52 rxRNA 52 pharmacodynamic effects 52 cariprazine 52 TPI ASM8 52 Maribavir 52 prGCD 52 HepaGam B 52 ZEVALIN 52 MAb 52 riociguat 52 candidate Zenvia 52 ataluren 52 Maxy G# 52 ALTU 52 antitumor activity 52 Actilon 52 azacitidine 52 Homspera TM 52 CXB# 52 adecatumumab 52 epigenetic therapies 52 Peramivir 52 compound AEZS 52 pharmacodynamic markers 52 drug conjugate 52 DsiRNA 51 Zoraxel 51 linaclotide 51 HDAC Inhibitor 51 picoplatin 51 intravenously administered 51 Aurora kinase 51 TRAIL receptor antibodies 51 Phase #/#a 51 CINTREDEKIN BESUDOTOX 51 radiation sensitizer 51 XOMA 3AB 51 Silodosin 51 Multimeric 51 NXL# 51 oral FTY# 51 OMNARIS HFA 51 GSK # 51 VA# [002] 51 Stapled Peptide 51 ABthrax TM 51 refractory APL 51 Phase Ib clinical trials 51 JOULFERON 51 MIS# 51 EZN 51 EGFr 51 class mGluR5 inhibitor 51 antitumour 51 Juvaris 51 MVA BN 51 Annamycin 51 Pafuramidine 51 PEP# [003] 51 Milatuzumab 51 monoclonal antibody 51 talabostat 51 administered subcutaneously 51 Linaclotide 51 telaprevir VX 51 rhC1INH 51 MyVax 51 phase 2a 51 pharmacokinetics pharmacodynamics 51 Accelerated Approval 51 sunitinib malate 51 CMV vaccine 51 Aviptadil 51 antitumor 51 vivo validation 51 PNP inhibitor 51 nanoviricide drug 51 anticancer therapeutics 51 G#DT 51 hA# 51 AMPAKINE CX# 51 mcg dose 51 Bioral 51 Pertuzumab 51 MLN# 51 Neugene 51 DAS# [001] 51 telomerase inhibitor 51 #D#C# 51 Loramyc R 51 TKM PLK1 51 APTIVUS r 51 advanced carcinoid 51 Iloperidone 51 PARP inhibitor 51 GVAX Pancreas Vaccine 51 Actemra tocilizumab 51 ZALBIN 51 Troxatyl 51 aprepitant 51 sorafenib tablets 51 Kevetrin ™ 51 PROVENGE 51 Talactoferrin 51 LHRH antagonist 51 sunitinib 51 delivered RNAi therapeutic 51 anti CD3 51 Azedra ™ 51 protein kinase inhibitor 51 retaspimycin 51 Sudhir Agrawal D.Phil 51 Phase Ib clinical 51 GGF2 51 pertuzumab 51 Atu# 51 monoclonal antibodies 51 EndoTAG 51 antiviral efficacy 51 peptide antigens 51 antiangiogenic therapy 51 drug ISA# 51 Regado 51 SparVax 51 Cloretazine 51 midstage clinical 51 Squalamine 51 Peregrine Pharmaceuticals